PATENT

4779US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In	re	Application	of:
----	----	-------------	-----

Noteborn et al.

Serial No.: To be assigned

Filed: July 11, 2001

For: USE OF APOPTOSIS INDUCING AGENTS IN THE TREATMENT OF

(AUTO)IMMUNE DISEASES

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 4992US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: <u>EL740550362US</u>

Date of Deposit with USPS: __July 11, 2001

Person making Deposit: _____ Jared Turner

Statement under 37 C.F.R. § 1.821(f)

Commissioner for Patents Washington, D.C. 20231

Sir:

- I, Allen C. Turner, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:
- 1. The enclosed paper copy of the SEQUENCE LISTING, as well as the enclosed copy of the SEQUENCE LISTING in computer readable form (CRF), are in compliance with the requirements of 37 C.F.R. §§ 1.821 through 1.825.

2. The enclosed copy of the SEQUENCE LISTING in computer readable form (CRF) is believed to be identical to the paper copy of the SEQUENCE LISTING.

Respectfully submitted,

Ällen C. Turnel

Registration No. 33,041 Attorney for Applicants

TRASK BRITT, PC

P. O. Box 2550

Salt Lake City, Utah 84110

Telephone: (801) 532-1922

Date: July 11, 2001

N:\2906\4992\Sequence listing statement.wpd